Pages Selected Financial Highlights Generic Activities Filed 14 Generic Product Applications TH Generic Premarin® (Conjugated Estrogens) Filed TH Five Patent Challenges Announced 10 New Generic Products Launched TH Five New Generic Oral Contraceptives TH Claravis TM (Generic Accutane®) TH Alternative Brand of Ciprofloxacin TH Tamoxifen, Tambocor, Fludrocortisone Corporate...
author: Lisa
Pages page 10
author: Lisa
Office of Drug Safety: Patient Labeling and Risk Communitation Food and Drug Administration • Center for Drug Evaluation and Research Office of Drug Safety Search Patient Labeling and Risk Communication FDA-Approved Patient Labeling Patient Package Inserts.- For some prescription medicines, FDA approves special patient materials to instruct patients about the safe use of the product
author: PhillipsJ
http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
Prescription and Over-the-Counter Drug Product List: 4/2003 45 -D- XCEL PHARMS 1MG/ML N05929 001 APR CFTG -A- AP + 1MG/ML N05929 001 APR CFTG -A- DIHYDROEROGTAMINE MESYLATE -A- AP PADDOCK 1MG/ML N40475 001 APR 28, 2003 APR NEWA DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE; ORAL -A- TAZTIA XT -A- AB4 ANDRX PHARMS 120MG N75401 001 APR 10, 2003 APR NEWA -A- AB4 180MG N75401 002 APR 10, 2003 APR NEWA -A- AB4 240MG N75401 003 APR 10, 2003 APR...
author: AUTHOR
Barr Pharmaceuticals, Inc. Contact Us Product Guide Drug Information Site Map Legal Notices Barr's web sites (the -Sites-) contain many valuable trademarks owned and/or used by Barr Pharmaceuticals, Inc.
AR 2007 Lo Res.pdf page 26
Pages page 59
author: Lisa
Pages page 11
author: Lisa
Pages page 3
author: Lisa
http://www.roche.com/pages/downloads/investor/pdf/praesentations/irphy230703chp.pdf 2 Roche First half 2003 Presentation to analysts Basle, Zurich, New YorkClaravis data source: IMS NPA prescription data
http://www.roche.com/pages/downloads/investor/pdf/praesentations/irphy230703ch.pdf 2 Roche First half 2003 Presentation to analysts Basle, Zurich, New YorkClaravis data source: IMS NPA prescription data
